Schmidt, Nathalie M. http://orcid.org/0000-0002-9841-8418
Wing, Peter A. C. http://orcid.org/0000-0002-2354-3281
Diniz, Mariana O.
Pallett, Laura J. http://orcid.org/0000-0002-4161-9462
Swadling, Leo http://orcid.org/0000-0002-0537-6715
Harris, James M. http://orcid.org/0000-0003-1880-3496
Burton, Alice R.
Jeffery-Smith, Anna
Zakeri, Nekisa http://orcid.org/0000-0003-1167-1160
Amin, Oliver E. http://orcid.org/0000-0003-3663-1253
Kucykowicz, Stephanie
Heemskerk, Mirjam H. http://orcid.org/0000-0001-6320-9133
Davidson, Brian
Meyer, Tim
Grove, Joe http://orcid.org/0000-0001-5390-7579
Stauss, Hans J. http://orcid.org/0000-0003-4340-7911
Pineda-Torra, Ines http://orcid.org/0000-0002-7349-2208
Jolly, Clare http://orcid.org/0000-0002-4603-2281
Jury, Elizabeth C. http://orcid.org/0000-0002-2389-3396
McKeating, Jane A. http://orcid.org/0000-0002-7229-5886
Maini, Mala K. http://orcid.org/0000-0001-6384-1462
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SCHM3310/1-1)
Cancer Research UK (26603, 26603)
Wellcome Trust (200838/Z/16/Z, 101849/Z/13/A)
RCUK | Medical Research Council (MR/R022011/1)
Article History
Received: 10 August 2020
Accepted: 9 April 2021
First Online: 14 May 2021
Competing interests
: The work described in this manuscript (combined immune-boosting and antiviral effects of ACAT inhibition in HBV and HBV-related HCC) is protected under an international patent application no.1917498.6 entitled Treatment of HBV Infection filed by applicant UCL Business Ltd. on 29 November 2019 with inventors named as M.K. Maini, N. Schmidt, A. Burton, P. Wing and J. McKeating. Unrelated to the content of this manuscript, the Maini laboratory has received unrestricted funding from Gilead, Roche and Immunocore. M.K.M. has sat on advisory boards/provided consultancy for Gilead Sciences, Hoffmann La Roche, Galapagos NV, GSK, and Freeline, with no funds being taken personally. L.J.P. has provided consultancy for Gilead Sciences. H.J.S. is a founder of Quell Therapeutics, shareholder of Quell Therapeutics, shareholder of Kuur Therapeutics and scientific advisor for PanCancerT. All remaining authors declare no competing interests.